Drugs in development · updated 11 November 2026
Rezetamig: clinical trials and development status
Other names and codes: JNJ-75348780
As of 11 November 2026 Rezetamig is in 3 active clinical trials (recruiting or ongoing, phases I–III) for 6 diseases. The most advanced phase is I.
Authorisation
- EU no (EMA)
- Italy not in the AIFA register
- Germany not available
- US no (FDA)
Sources: EMA, AIFA register (open data), FDA. For Germany only the EU centralised authorisation is shown: the national BfArM register is not one of our sources.
Map of sites in Europe with recruitment status, every trial and an email when something changes. Full access free until 31 March 2027, no card needed.
What it is
A human bispecific antibody, with potential antineoplastic activity. Rezetamig contains two binding sites, one for the tumor-associated antigen (TAA) CD22, and one for the T-cell surface antigen CD3. Upon administration, rezetamig binds to both CD3 on T-cells and CD22-expressing B-lineage tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the CD22-expressing tumor B-cells. CD22 is exclusively expressed on B-cells and is often overexpressed in B-lymphocytic malignancies. It negatively regulates the B-cell receptor.
Diseases studied
For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.
| Disease | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Non-Hodgkin lymphoma | I | 3 | NCT06788509 |
| Acute myeloid leukemia | I | 1 | NCT06788509 |
| Castration-resistant prostatic neoplasm | I | 1 | NCT06788509 |
| Chronic lymphocytic leukemia | I | 1 | NCT06788509 |
| Myelodysplastic Syndromes | I | 1 | NCT06788509 |
| Neoplasm | I | 1 | NCT06788509 |
Sites in Europe
24 sites of the active trials in 7 European countries, 0 recruiting.
- Spain9
- Denmark4
- France3
- Poland3
- United Kingdom3
- Belgium1
- Greece1
Sites declared by the sponsors on ClinicalTrials.gov; region worked out by Phuturdex from the geographic point. The list of sites with city and recruitment status is in the app. See the sites →
Everything on Rezetamig
In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.
Open in Phuturdex →Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 11 November 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, refers to the United States and is a Phuturdex calculation described on the Method page, not official data: the drug may already be marketed in other countries.